캐나다 - 영어 - Health Canada

baxter corporation - water - liquid - 100% - water 100% - irrigating solutions

캐나다 - 영어 - Health Canada

vetoquinol n a inc - lidocaine (lidocaine hydrochloride monohydrate) - solution - 20mg - lidocaine (lidocaine hydrochloride monohydrate) 20mg - cattle; horses; cats; dogs

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

biocodex - nefopam (nefopam hydrochloride) - solution for injection - 10mg/ml

캐나다 - 영어 - Health Canada

alberta veterinary laboratories ltd - lidocaine hydrochloride - solution - 20mg - lidocaine hydrochloride 20mg - cattle; swine (pigs); horses; cats; sheep; dogs

말레이시아 - 영어 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - nefopam hydrochloride -

싱가포르 - 영어 - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - the evo iq volumetric pump system is intended for use in a wide variety of patient care environments that includes adult, pediatric, and neonatal. the evo iq volumetric pump system facilitates the delivery of routine critical infusion therapies via continuous and intermittent delivery using primary and secondary infusion modes.

미국 - 영어 - NLM (National Library of Medicine)

accord biopharma, inc. - leuprolide mesylate (unii: 8e3c3c493w) (leuprolide - unii:efy6w0m8tg) - camcevi is indicated for the treatment of adult patients with advanced prostate cancer. camcevi is contraindicated in patients known to be hypersensitive to gnrh, gnrh agonist analogs, or any of the excipients in camcevi. anaphylactic reactions to gnrh agonist analogs have been reported in the medical literature. risk summary based on findings in animal studies and mechanism of action, camcevi can cause fetal harm when administered to a pregnant woman [see clinical pharmacology ( 12.1)]. there are no available data in pregnant women to inform the drug-associated risk. in animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose

미국 - 영어 - NLM (National Library of Medicine)

foresee pharmaceuticals co., ltd. - leuprolide mesylate (unii: 8e3c3c493w) (leuprolide - unii:efy6w0m8tg) - camcevi is indicated for the treatment of adult patients with advanced prostate cancer. camcevi is contraindicated in patients known to be hypersensitive to gnrh, gnrh agonist analogs, or any of the excipients in camcevi. anaphylactic reactions to gnrh agonist analogs have been reported in the medical literature. risk summary based on findings in animal studies and mechanism of action, camcevi can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. in animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose (see data) . advise pregnant patients and females of reproductive potential of the potential risk to